CNTBNot HalalF
Unlock full report, free

Is Connect Biopharma Holdings (CNTB) Stock Halal?

Compliance Status

Not Halal

Screened on Nov 11, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Connect Biopharma Holdings Limited (CNTB) halal? Not Halal. Based on AAOIFI screening, Connect Biopharma Holdings Limited passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Connect Biopharma Holdings Limited (CNTB) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 11, 2026. Source: https://halalscreener.app/en/stock/CNTB

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

1.4% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding CNTB

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Share this verdict

A receipt-style image with the math on it, so whoever you send it to can check it.

Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

NASDAQHealthcareUS

$0.69

Market Cap: 43.4M

Get an email if CNTB's halal status changes

We re-screen Connect Biopharma Holdings Limited daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Interest-bearing deposits are over the 30% limit.
  • Income from prohibited sources is over the 5% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Nov 11, 2026
AI Compliance InsightProSee plans
Revenue BreakdownProSee plans

Compliance History

  1. Not Halalnow

    since Sep 2026

  2. Under Review

    until the change above

  3. Not Halal

    until the change above

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR
Free · No credit card required

Know the day CNTB's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Connect Biopharma Holdings Limited (CNTB) halal to invest in?
Connect Biopharma Holdings Limited (CNTB) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Connect Biopharma Holdings Limited get a F compliance rating?
Connect Biopharma Holdings Limited (CNTB) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.4% (limit 30%); interest-bearing deposits over the 30% limit; prohibited income over the 5% limit. The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Connect Biopharma Holdings Limited's Shariah verdict?
Connect Biopharma Holdings Limited's verdict is recalculated at every re-screen, including the one that follows each new quarterly or annual report. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Connect Biopharma Holdings Limited re-screened for Shariah compliance?
Connect Biopharma Holdings Limited (CNTB) is screened from the latest financial statements on record, currently those for fiscal Q2 2026. The 500 largest US-listed companies, and every stock on a HalalScreener watchlist or portfolio, are re-screened daily against the current market cap; every other stock at least once a week. When the company files a new quarterly or annual report with the SEC, it is re-screened from that filing: we check the SEC's filing feed every 15 minutes and the earnings calendar every day. Last screened: Nov 11, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.